Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients
- 129 Downloads
Patients with either primary or metastatic brain tumors quite often have cognitive impairment. Maintaining cognitive function is important to brain tumor patients and a decline in cognitive function is generally accompanied by a decline in functional independence and performance status. Cognitive decline can be a result of tumor progression, depression/anxiety, fatigue/sleep dysfunction, or the treatments they have received. It is our opinion that providers treating brain tumor patients should obtain pre-treatment and serial cognitive testing in their patients and offer mitigating and therapeutic interventions when appropriate. They should also support cognition-focused clinical trials.
KeywordsCognition Brain Radiation Neuropsychology Memory Attention
Compliance with Ethical Standards
Conflict of Interest
Christina K. Cramer has received speaker’s honoraria from Monteris Medical, and is also a member of teaching faculty for an on-site SBRT training course to which Elekta refers customers and for which Elekta reimburses the department.
Tiffany L. Cummings declares that she has no conflict of interest.
Rachel N. Andrews declares that she has no conflict of interest.
Michael Chan has received speaker’s honoraria from Monteris Medical, and is also a member of teaching faculty for an on-site SBRT training course to which Elekta refers customers and for which Elekta reimburses the department.
Roy Strowd declares that he has no conflict of interest.
Stephen R. Rapp declares that he has no conflict of interest.
Edward G. Shaw declares that he has no conflict of interest.
Glenn J. Lesser has received clinical trial support from Vascular Biogenics, Incyte, NewLink Genetics, Novartis, Immunocellular Therapeutics, and Pfizer; has received compensation from Monteris Medical and Insys Therapeutics for service as a consultant; and has received compensation from Stemline Therapeutics for serving as Data Safety and Monitoring Board Chair for a study.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 2013;15(10):1429–37 This randomized, placebo-controlled study did not meet its pre-specified primary endpoint but did show that time to cognitive decline is longer in patients who receive memantine during and after WBRT.PubMedPubMedCentralGoogle Scholar
- 5.•• Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653–9 This was a seminal randomized, phase III, open-label, placebo-controlled trial enrolled irradiated brain tumor survivors (at least 6 months after RT) and evaluated cognition before treatment with donepezil or placebo and then after 24 weeks of medication. This study did not meet its pre-specified primary endpoint but patients randomized to donepezil performed better on measures of verbal and working memory (HVLT-DR and -IR). There was also an interaction effect between pre-randomization (baseline) cognitive performance and treatment group—patients with poorer initial cognitive functioning benefited more from donepezil. For this reason, donepezil continues to be used in the clinic.PubMedPubMedCentralGoogle Scholar
- 6.• Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–501 This was a randomized, open-label, placebo-controlled phase III trial of methylphenidate taken during brain RT and for 8 weeks after, showed no difference fatigue or cognition between patients taking methylphenidate and those taking placebo. This study was hindered by a higher than expected drop-out rate which may have left it underpowered to detect a true difference. There are other smaller studies to support the use of methylphenidate in treating cancer-related fatigue which is why methylphenidate is still used clinically.PubMedGoogle Scholar
- 7.Attia A, Rapp SR, Case LD, D’Agostino R, Lesser G, Naughton M, et al. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neuro-Oncol. 2012;109(2):357–63.Google Scholar
- 8.• Gehring K, Sitskoorn MM, Gundy CM, Sikkes SA, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27(22):3712–22 In this study, low-grade glioma survivors with stable disease were randomized to a cognitive rehabilitation program or the wait list. The program consisted 7 weeks of rehabilitation. Immediately after treatment, patients who participated in the rehabilitation program reported improved cognitive functioning on questionnaires but did not perform better on objective measures of cognitive performance. However, after 6 months, the patients who underwent rehabilitation performed objectively better on measures of verbal memory and attention compared to control patients and reported less mental fatigue.PubMedGoogle Scholar
- 10.Lee TC, Greene-Schloesser D, Payne V, Diz DI, Hsu FC, Kooshki M, et al. Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment. Radiat Res. 2012;178(1):46–56.PubMedPubMedCentralGoogle Scholar
- 14.Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6.PubMedPubMedCentralGoogle Scholar
- 16.Andrews RN, Metheny-Barlow LJ, Peiffer AM, Hanbury DB, Tooze JA, Bourland JD, et al. Cerebrovascular remodeling and neuroinflammation is a late effect of radiation-induced brain injury in non-human primates. Radiat Res. 2017.Google Scholar
- 17.Hanbury DB, Robbins ME, Bourland JD, Wheeler KT, Peiffer AM, Mitchell EL, et al. Pathology of fractionated whole-brain irradiation in rhesus monkeys ( Macaca mulatta ). Radiat Res. 2015.Google Scholar
- 20.Ungvari Z, Podlutsky A, Sosnowska D, Tucsek Z, Toth P, Deak F, et al. Ionizing radiation promotes the acquisition of a senescence-associated secretory phenotype and impairs angiogenic capacity in cerebromicrovascular endothelial cells: role of increased DNA damage and decreased DNA repair capacity in microvascular radiosensitivity. J Gerontol A Biol Sci Med Sci. 2013;68(12):1443–57.PubMedPubMedCentralGoogle Scholar
- 31.Ji S, Tian Y, Sun R, Lu Y, Zhang L, Chen L, et al. Radiation-induced hippocampal neurogenesis impairment and cognitive deficits is associated with inhibition of BDNF-Trk-B signaling. Int J Radiat Oncol Biol Phys. 87(2):S628.Google Scholar
- 52.• Peiffer AM, Leyrer CM, Greene-Schloesser DM, Shing E, Kearns WT, Hinson WH, et al. Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology. 2013;80(8):747–53 This was an important analysis of several prospective studies which linked post-RT cognitive function to the dose distribution in the brain relative to specific anatomic regions-of-interest. This suggests that ultimatley, a dose-volume-histogram analysis of neural substructures could help predict (and reduce the risk) of RICD.PubMedPubMedCentralGoogle Scholar
- 72.Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.PubMedPubMedCentralGoogle Scholar
- 75.Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.Google Scholar
- 76.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedPubMedCentralGoogle Scholar
- 78.American Psychiatric Association. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994. xxvii, 886 p. p.Google Scholar
- 79.Gifford A, Lawrence J, Case D, Rapp S, Baker L, Craft S, et al. Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors. J Clin Oncol. 2015;33(15):9560.Google Scholar
- 80.Gifford AR, Lawrence JA, Baker LD, Balcueva EP, Case D, Craft S, et al. National Institute on Aging /Alzheimer’s Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors. J Oncol Res. 2017;1(1).Google Scholar
- 81.Cramer CK, McKee N, Case LD, Chan MD, Cummings TL, Lesser GJ, et al. Mild cognitive impairment in long-term brain tumor survivors following brain irradiation. J Neurooncol. 2018.Google Scholar
- 86.van der Linden SD, Sitskoorn MM, Rutten GM, Gehring K. Feasibility of the evidence-based cognitive telerehabilitation program Remind for patients with primary brain tumors. J Neuro-Oncol. 2018;137(3):523–32.Google Scholar
- 87.•• Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44 This randomized trial of SRS alone versus SRS + WBRT for patients with a limited number of brain metastases demonstrated that treating patients with SRS rather than WBRT can preserve their cognition without compromising overall survival. At 4 months, only 24% of patients receiving SRS had declined in their HVLT-R score compared to 52% of patients in the WBRT arm.PubMedGoogle Scholar
- 88.•• Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9 N0574 randomized patients with 1–3 brain metastases to SRS alone or SRS + WBRT and showed a much higher incidence of cognitive decline in the group receiving WBRT than those receiving SRS alone.PubMedPubMedCentralGoogle Scholar
- 89.•• Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60 NCGTGN107C/CEC 3 offered confirmation that cognitive-deterioration-free survival is longer in patients receiving SRS compared to WBRT. In this phase III trial, 194 patients who had undergone resection for a brain metastasis < 5 cm were randomized to postoperative SRS to the surgical cavity or WBRT . At 6 months, 52% of patients receiving SRS had cognitive decline compared with 85% of the patients receiving WBRT. Again, there was no difference seen in survival between the two groups. This was a landmark trial and will likely serve as a benchmark and historical control study for some years to come.PubMedPubMedCentralGoogle Scholar
- 90.•• Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome WA, Bruner DW, et al. Preservation of neurocognitive function (NCF) with conformal avoidance of the hippocampus during whole-brain radiotherapy (HA-WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2018;102(5):1607 This is an initial report of a trial looking at WBRT plus memantine versus WBRT with hippocampal avoidance plus memantine (CC001). The early results indicate that time to cognitive decline is longer in the hippocampal avoidance + memantine versus WBRT + memantine.Google Scholar
- 91.Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem. 2002;82(3):615–24.Google Scholar
- 93.Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004;88(2):494–501.Google Scholar
- 96.Cramer CK, Alphonse-Sullivan N, Isom S, Metheny-Barlow LJ, Cummings TL, Page BR, et al. Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial. J Cancer Res Clin Oncol. 2018.Google Scholar